Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging.

Frigerio B, Franssen G, Luison E, Satta A, Seregni E, Colombatti M, Fracasso G, Valdagni R, Mezzanzanica D, Boerman O, Canevari S, Figini M.

Oncotarget. 2017 Feb 14;8(7):10919-10930. doi: 10.18632/oncotarget.14229.

2.

Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen.

Frigerio B, Benigni F, Luison E, Seregni E, Pascali C, Fracasso G, Morlino S, Valdagni R, Mezzanzanica D, Canevari S, Figini M.

Immunol Lett. 2015 Nov;168(1):105-10. doi: 10.1016/j.imlet.2015.09.012. Epub 2015 Sep 25.

PMID:
26404855
3.

Computational design of novel peptidomimetic inhibitors of cadherin homophilic interactions.

Doro F, Colombo C, Alberti C, Arosio D, Belvisi L, Casagrande C, Fanelli R, Manzoni L, Parisini E, Piarulli U, Luison E, Figini M, Tomassetti A, Civera M.

Org Biomol Chem. 2015 Mar 7;13(9):2570-3. doi: 10.1039/c4ob02538e.

4.

Targeting FR-expressing cells in ovarian cancer with Fab-functionalized nanoparticles: a full study to provide the proof of principle from in vitro to in vivo.

Quarta A, Bernareggi D, Benigni F, Luison E, Nano G, Nitti S, Cesta MC, Di Ciccio L, Canevari S, Pellegrino T, Figini M.

Nanoscale. 2015 Feb 14;7(6):2336-51. doi: 10.1039/c4nr04426f.

PMID:
25504081
5.

A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer.

Frigerio B, Fracasso G, Luison E, Cingarlini S, Mortarino M, Coliva A, Seregni E, Bombardieri E, Zuccolotto G, Rosato A, Colombatti M, Canevari S, Figini M.

Eur J Cancer. 2013 Jun;49(9):2223-32. doi: 10.1016/j.ejca.2013.01.024. Epub 2013 Feb 20.

PMID:
23433847
6.

Antitumor effects of a human dimeric antibody fragment 131I-AFRA-DFM5.3 in a mouse model for ovarian cancer.

Zacchetti A, Martin F, Luison E, Coliva A, Bombardieri E, Allegretti M, Figini M, Canevari S.

J Nucl Med. 2011 Dec;52(12):1938-46. doi: 10.2967/jnumed.110.086819. Epub 2011 Nov 8.

7.

Role of tyrosyl-DNA phosphodiesterase 1 and inter-players in regulation of tumor cell sensitivity to topoisomerase I inhibition.

Perego P, Cossa G, Tinelli S, Corna E, Carenini N, Gatti L, De Cesare M, Ciusani E, Zunino F, Luison E, Canevari S, Zaffaroni N, Beretta GL.

Biochem Pharmacol. 2012 Jan 1;83(1):27-36. doi: 10.1016/j.bcp.2011.09.021. Epub 2011 Sep 29.

PMID:
21978643
8.

(177)Lu- labeled MOv18 as compared to (131)I- or (90)Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts.

Zacchetti A, Coliva A, Luison E, Seregni E, Bombardieri E, Giussani A, Figini M, Canevari S.

Nucl Med Biol. 2009 Oct;36(7):759-70. doi: 10.1016/j.nucmedbio.2009.05.004. Epub 2009 Jul 29.

PMID:
19720288
9.

Conversion of murine antibodies to human antibodies and their optimization for ovarian cancer therapy targeted to the folate receptor.

Figini M, Martin F, Ferri R, Luison E, Ripamonti E, Zacchetti A, Mortarino M, Di Cioccio V, Maurizi G, Allegretti M, Canevari S.

Cancer Immunol Immunother. 2009 Apr;58(4):531-46. doi: 10.1007/s00262-008-0575-5. Epub 2008 Aug 15.

PMID:
18704410
10.

Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment.

Bagnoli M, Balladore E, Luison E, Alberti P, Raspagliesi F, Marcomini B, Canevari S, Mezzanzanica D.

Mol Cancer Ther. 2007 Feb;6(2):762-72.

11.

90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas.

Coliva A, Zacchetti A, Luison E, Tomassetti A, Bongarzone I, Seregni E, Bombardieri E, Martin F, Giussani A, Figini M, Canevari S.

Cancer Immunol Immunother. 2005 Dec;54(12):1200-13. Epub 2005 May 31.

PMID:
15926078
12.

CD95-mediated apoptosis is impaired at receptor level by cellular FLICE-inhibitory protein (long form) in wild-type p53 human ovarian carcinoma.

Mezzanzanica D, Balladore E, Turatti F, Luison E, Alberti P, Bagnoli M, Figini M, Mazzoni A, Raspagliesi F, Oggionni M, Pilotti S, Canevari S.

Clin Cancer Res. 2004 Aug 1;10(15):5202-14.

13.

Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies.

Figini M, Ferri R, Mezzanzanica D, Bagnoli M, Luison E, Miotti S, Canevari S.

Gene Ther. 2003 Jun;10(12):1018-25.

PMID:
12776159
14.

The humoral immune response to macrocyclic chelating agent DOTA depends on the carrier molecule.

Perico ME, Chinol M, Nacca A, Luison E, Paganelli G, Canevari S.

J Nucl Med. 2001 Nov;42(11):1697-703.

15.

Production and validation of the pharmacokinetics of a single-chain Fv fragment of the MGR6 antibody for targeting of tumors expressing HER-2.

Turatti F, Mezzanzanica D, Nardini E, Luison E, Maffioli L, Bambardieri E, de Lalla C, Canevari S, Figini M.

Cancer Immunol Immunother. 2001 Feb;49(12):679-86.

PMID:
11258794
16.

Development of a new vaccine formulation that enhances the immunogenicity of tumor-associated antigen CaMBr1.

Perico ME, Mezzanzanica D, Luison E, Alberti P, Panza L, Russo G, Canevari S.

Cancer Immunol Immunother. 2000 Aug;49(6):296-304.

PMID:
10946811
17.

IgG2a induced by interleukin (IL) 12-producing tumor cell vaccines but not IgG1 induced by IL-4 vaccine is associated with the eradication of experimental metastases.

Rodolfo M, Melani C, Zilocchi C, Cappetti B, Luison E, Arioli I, Parenza M, Canevari S, Colombo MP.

Cancer Res. 1998 Dec 15;58(24):5812-7.

18.

Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody.

Melani C, Figini M, Nicosia D, Luison E, Ramakrishna V, Casorati G, Parmiani G, Eshhar Z, Canevari S, Colombo MP.

Cancer Res. 1998 Sep 15;58(18):4146-54.

19.

Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization.

Casalini P, Luison E, Ménard S, Colnaghi MI, Paganelli G, Canevari S.

J Nucl Med. 1997 Sep;38(9):1378-81.

Supplemental Content

Loading ...
Support Center